AU2001260076A1 - Compounds for treating disorders where a decreased level of plasma ffa is desired - Google Patents

Compounds for treating disorders where a decreased level of plasma ffa is desired

Info

Publication number
AU2001260076A1
AU2001260076A1 AU2001260076A AU6007601A AU2001260076A1 AU 2001260076 A1 AU2001260076 A1 AU 2001260076A1 AU 2001260076 A AU2001260076 A AU 2001260076A AU 6007601 A AU6007601 A AU 6007601A AU 2001260076 A1 AU2001260076 A1 AU 2001260076A1
Authority
AU
Australia
Prior art keywords
compounds
treating disorders
decreased level
plasma ffa
ffa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001260076A
Inventor
Hector Beltrandelrio
Johannes Cornelis De Jong
Poul Jacobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2001260076A1 publication Critical patent/AU2001260076A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2001260076A 2000-05-15 2001-05-15 Compounds for treating disorders where a decreased level of plasma ffa is desired Abandoned AU2001260076A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000786 2000-05-15
DKPA200000786 2000-05-15
US20640100P 2000-05-23 2000-05-23
US60206401 2000-05-23
PCT/DK2001/000341 WO2001087843A1 (en) 2000-05-15 2001-05-15 Compounds for treating disorders where a decreased level of plasma ffa is desired

Publications (1)

Publication Number Publication Date
AU2001260076A1 true AU2001260076A1 (en) 2001-11-26

Family

ID=26068823

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001260076A Abandoned AU2001260076A1 (en) 2000-05-15 2001-05-15 Compounds for treating disorders where a decreased level of plasma ffa is desired

Country Status (3)

Country Link
US (1) US20020082254A1 (en)
AU (1) AU2001260076A1 (en)
WO (1) WO2001087843A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040068240A (en) 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
EP1636201A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Para-substituted phenyl carbamates as inhibitors of hormone sensitive lipase
CA2526204A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
AU2004247320A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase
WO2004111006A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Para-subtituted phenyl carbamates as inhibitors of hormone sensitive lipase
WO2004111004A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1358684A (en) * 1970-06-15 1974-07-03 Novo Terapeutisk Labor As Carboxylic acids
GB1419377A (en) * 1972-01-05 1975-12-31 Fisons Ltd Pyridine derivatives
FR2253011A1 (en) * 1973-11-30 1975-06-27 Ici Ltd Ammonio-amidates for modifying polymers or polymer surfaces - are prepd. from hydrazides pref. prepd. in situ from quaternary hydrazines
DK62692D0 (en) * 1992-05-14 1992-05-14 Novo Nordisk As
JPH0812573A (en) * 1994-06-24 1996-01-16 Mitsubishi Chem Corp Free fatty acid reducing agent

Also Published As

Publication number Publication date
WO2001087843A8 (en) 2002-02-07
US20020082254A1 (en) 2002-06-27
WO2001087843A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AUPR596301A0 (en) A method of microwave treatment of wood
AU2001275509A1 (en) An electro-fluidic assembly process for integration of electronic devices onto asubstrate
AU2001247696A1 (en) Plasma treatment of filter media
AU2001266068A1 (en) Treatment of mineral substrates
AU2001294764A1 (en) Process for reduction of gaseous sulfur compounds
AU2207400A (en) A method for the prophylactic treatment of cataracts
AU7288100A (en) Regulation of secondary metabolite production
AU2001241496A1 (en) A method of improving photomask geometry
AU2002227958A1 (en) Use of moulding compounds for producing treatment devices
AU3977700A (en) Method of treating neurological disorders
AU2001260076A1 (en) Compounds for treating disorders where a decreased level of plasma ffa is desired
AU2001271782A1 (en) Use of substituted insole compounds for treating excessive intraocular pressure
AU2001253749A1 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
AU4552200A (en) Method of treating psychotic disorders
AU2002233210A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence
AU2001239510A1 (en) Treatment of renal disorders
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU2001273640A1 (en) Method for dewatering of sludge
AU3757300A (en) Method of treating anxiety disorders
AU2001288792A1 (en) Method of treating neurologic disorders
AU2001290166A1 (en) Components of canola for treating hyperlipidemia
AUPR211500A0 (en) A method of treating sewage
AUPQ528900A0 (en) A treatment process for removal of chloranisole compounds
AU2002233209A1 (en) Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
AU2002223688A1 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence